ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Translational Session

APOL1: The Dawning of the Era of Treatment

November 10, 2019 | 10:00 AM - 12:00 PM

Location: 150, Walter E. Washington Convention Center

Session Description

This session reviews the expanding spectrum of APOL1-associated disease, mechanisms whereby APOL1 kidney-risk variants may produce cellular dysfunction, the targeting of modifying factors and potential for antisense oligonucleotide (ASO) therapy to prevent formation of APOL1 kidney-risk variant proteins, and the application of genomics and precision medicine in ESKD.

Learning Objective(s)

  • Discuss the spectrum of APOL1-associated disease
  • Describe the mechanisms whereby APOL1 renal-risk variant proteins cause renal cell death
  • Present the evidence for ASO therapy in the treatment of inherited disease
  • Discuss the use of genetic data in personalized medicine in patients with CKD

Learning Pathway(s)

  • Chronic Kidney Disease
  • Genetic Diseases of the Kidneys


  • Barry I. Freedman, MD
  • Ebele M. Umeukeje, MD, MPH

Patient Voice/Commentator

  • Patrick O. Gee, PhD


  • APOL1 Variants in the General Population and Among Transplant Recipients
    10:00 AM - 10:30 AM
    Orlando M. Gutierrez, MD 
  • Mechanisms of the APOL1 Kidney-Risk Variant Associated Disease
    10:30 AM - 11:00 AM
    Leslie A. Bruggeman, PhD 
  • Antisense Oligonucleotide Therapy for APOL1-Associated Nephropathy
    11:00 AM - 11:30 AM
    Mariam Aghajan, PhD 
  • Genomics and Precision Medicine in ESKD
    11:30 AM - 12:00 PM
    Cheryl Ann Winkler, PhD